These findings elucidated the underlying mechanisms of the tumor suppressive property of PARK2 in NSCLC, which inhibited the EGFR/AKT/mTOR pathway to suppress the growth, metastasis and promotes apoptosis of NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.